ClinicalTrials.Veeva

Menu

One Research on Improving Cognitive Impairment Caused by Hypertension

J

Jiangsu Famous Medical Technology

Status

Unknown

Conditions

Hypertension

Study type

Observational

Funder types

Industry

Identifiers

NCT03943420
BE2017770

Details and patient eligibility

About

Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive impairment caused by hypertension.

Full description

Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive impairment caused by hypertension.

The investigators designed a multi-center randomized controlled clinical trial to study the security and effectiveness of this therapy.

Enrollment

144 estimated patients

Sex

All

Ages

55 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged 55 to 75 years old, male or female;
  • Having a history of hypertension for more than 2 years but can maintain SBP ≤ 140 mmHg and BDP ≤ 90 mmHg with medication;
  • 21 ≤ MMSE < 26, or 14 ≤ MoCA < 26, CDR < 0.5. Bseides, the chief complaint must happen after having hypertension;
  • Meet TCM Syndrome Differentiation Standard:according to the Guidelines for the Clinical Research of Chinese Medicine New Drugs ( published by China Medical Science Press ) :Overabundant liver-fire type:dizziness and headache, both face and eyes are red, dry mouth and bitter taste in mouth, red tongue with yellowish coating, wire and frequent pulse. Yin deficiency and yang hyperactivity type: dizziness and headache, Tinnitus and forgetfulness, sphoria with feverish sensation in chest & palms & soles, palpitation and insomnia, red tongue & thin white or less coating, wiry weak and numbered pulse;
  • CTMRI hint: leukoaraiosis and no sign of Cerebral infarction;
  • Patients or the guardian hold the right opinions over the research and are willing to obey researcher's orders;
  • Having a certain degree of education (being able to read simple newspapers in the past);
  • Patients agree to sign informed consent。

Exclusion criteria

  • Secondary hypertension;
  • Taking certain kinds of antihypertensive drugs which may damage brain cognitive function;
  • Diagnosed as depression or other mental disorders according to DSM-IV;
  • Diagnosed as vascular dementia according to diagnostic criteria, CDR ≥ 0.5; alzheimer disease or dementia caused by some other reasons (including mixed dementia according to diagnostic criteria for VCI); cognitive impairment due to head injury。
  • Suffering from certain kinds of diseases which may interfere the assessment of cognitive function, including those who are diagnosed as alcoholics and drugs or psychotropic medicine abusers during the last 5 years according to DSM-IV;
  • Accompanied with severe neurological function disorder;
  • Asthma, chronic severe primary cardiovascular disease, liver lesion, hematological lesions, lung diseases, diabetes or other severe diseases may influence the patients' survival such as cancer or AIDS;
  • Other: Such as poor compliance, or can not attend the follow-up visit in time for some reasons;
  • Taking the same kind of medicine during the last 30 days which may influence the trial;
  • Is participating in another clinical study;
  • Not up to TCM Syndrome Differentiation Standard。

Trial design

144 participants in 3 patient groups

Experimental Group
Description:
Therapy A : Basic treatment + Qianyang Yuyin Granules
Negative Control Group
Description:
Therapy B : Basic treatment
Positive Control Group
Description:
Therapy C : Basic treatment + Donepezil

Trial contacts and locations

1

Loading...

Central trial contact

Cheng Chang, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems